ESPE2023 Poster Category 1 GH and IGFs (48 abstracts)
Assessing the treatment burden and Quality of Life of children receiving daily recombinant Growth Hormone treatment in Greece
Athanasios Christoforidis 1,2 , Assimina Galli-Tsinopoulou 3,4 , Fotini-Eleni Karachaliou 5 , Dionisios Chrysis 6 , Christina Kanaka – Gantenbein 7,8 , Ioannis Skiadas 9 , Oresteia Zisimopoulou 9 , Apostolia Poimenidou 9 , Manfred Windisch 10 , Nikoletta Sofiaki 9 & Evangelia Baxevanidi 9
11st Pediatric Department, Ippokratio General Hospital, Thessaloniki, Greece. 2Aristotle University of Thessaloniki, Thessaloniki, Greece. 32nd Department of Pediatrics, Aristotle University of Thessaloniki, Thessaloniki, Greece. 4AΗEPA University General Hospital, Thessaloniki, Greece. 5University Pediatric Clinic, Attikon Hospital, Athens, Greece. 6Department of Pediatrics, University Hospital of Patras, Patras, Greece. 7Division of Endocrinology, Diabetes and Metabolism and Aghia Sophia Children’s Hospital Endo-ERN representative, Athens, Greece. 81st Department of Pediatrics, Medical School, National and Kapodistrian University of Athens, Aghia Sofia Children’s Hospital, Athens, Greece. 9Pfizer Hellas S.A., Athens, Greece. 10Pfizer Corporation Austria Gesellschaft M.B.H., Vienna, Austria
Background: Pediatric growth hormone deficiency (pGHD) is associated with growth attenuation/deceleration, short stature, delayed bone maturation, and metabolic defects. Daily recombinant human growth hormone (rhGH) treatment promotes linear growth and increases growth rate; however, it may present a substantial burden for patients and caregivers. This may lead to low adherence, limiting the clinical effect of treatment. This study assesses the health-related quality of life (HRQoL) of children and adolescents with GHD, as well as rhGH treatment burden for patients and caregivers in Greece.
Methods: This ongoing cross-sectional study enrolls patients aged 3-17 years receiving daily rhGH for at least 12 months. The Quality of Life in Short Stature Youth (QoLISSY) questionnaire assessed patients’ HRQoL (higher score denoting better HRQoL) from both patients’ and caregivers’ perspective, whereas the Life Interference Questionnaire for Growth Hormone Deficiency (LIQ-GHD) evaluated patients’ and caregivers’ treatment burden (higher score denoting greater life interference).
Results: Overall, 84 patients (77 aged >8 years) from 5 pediatric endocrinology outpatient clinics were included in this interim analysis (July 2022-January 2023). The mean QoLISSY scores reported from patients and caregivers were 81.18 and 74.92, respectively. Coping was the lowest scored domain in both groups, followed by Treatment and Beliefs domains (Table 1). The LIQ-GHD results were similar to literature reports, revealing a mean (SD) overall patient life interference score of 22.36 (±19.36) with no substantial differences among age groups. The mean (SD) caregiver life interference score was 15.86 (±18.48). In a four-week period, 46.43% of patients missed ≥1 injections. Adolescents (>12 years) demonstrated lower adherence than patients 8-12 and <8 years of age (47.62% vs. 60.00% vs. 57.14%, respectively).
| QoLISSY scores | Overall (patient report*) n= 77 Mean (SD) | Overall (caregiver report**) n= 84 Mean (SD) |
| Total | 81.18 (±15.05) | 74.92 (±18.63) |
| Physical domain | 82.25 (±15.30) | 78.37 (±19.28) |
| Social domain | 80.64 (±18.56) | 75.74 (±21.63) |
| Emotional domain | 80.64 (±17.01) | 70.65 (±20.13) |
| Coping domain | 46.88 (±23.51) | 50.54 (±20.39) |
| Beliefs domain | 70.45 (±27.41) | 66.67 (±27.43) |
| Treatment domain | 56.19 (±21.36) | 61.37 (±19.90) |
| SD: standard deviation; *patients aged >8 years; **patients aged 3-17 years | ||
Conclusion: This analysis showed an overall good HRQoL and a moderate treatment burden for patients receiving daily rhGH and their caregivers. However, sub-optimal adherence rates may affect clinical outcomes. New treatment options could further improve HRQoL and treatment experience, as well as increase adherence rates that may lead to better health outcomes.
Article tools
My recent searches
My recently viewed abstracts
Authors
ESPE Abstracts
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more